TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23044387

Group type: EXPERIMENTAL
Intervention: FluroShield (F) sealant
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma (H) sealant
Number of subjects: 72

Group type: COMPARATOR
Intervention: All groups (including both sealants)
Number of subjects: 72
Study: 21729974

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Casting
Number of subjects: 69

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 69
Study: 19632965

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT) for 6 hours a day during waking hours for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional therapy only (Control)
Number of subjects: 27
Study: 17489733

Group type: EXPERIMENTAL
Intervention: ERCC1 as a marker for resistance to cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular markers (e.g., ERCC1)
Number of subjects: 0
Study: 16253073

Group type: EXPERIMENTAL
Intervention: TUMT followed by BD
Number of subjects: 40

Group type: COMPARATOR
Intervention: TUMT alone
Number of subjects: 40
Study: 12201933

Group type: EXPERIMENTAL
Intervention: alpha-1 adrenoceptor antagonists (alpha-1ARA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: preoperative untreated group
Number of subjects: 39
Study: 9659537

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Theophylline (oral dose titrated twice daily)
Number of subjects: 112
Study: 8133107

Group type: EXPERIMENTAL
Intervention: Natural rotavirus infection
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Asymptomatic rotavirus infection
Number of subjects: 235
Study: 2777567

Group type: EXPERIMENTAL
Intervention: Experimental group (received touch and verbal interaction during weaning)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (did not receive touch and verbal interaction)
Number of subjects: 26
Study: 4808433

Group type: EXPERIMENTAL
Intervention: Ellsworth House community rehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (remained in the jail system)
Number of subjects: 0
Study: 31866387

Group type: EXPERIMENTAL
Intervention: Chain community pharmacies (CVS, Walgreens, etc.)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Areas with high opioid mortality rates
Number of subjects: 434

Group type: COMPARATOR
Intervention: Areas with low opioid mortality rates
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Overall community pharmacies
Number of subjects: 434
Study: 30403817

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60% VO2peak) for 45 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Seated rest for 45 minutes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) post-exercise (24 hours)
Number of subjects: 24
Study: 27598045

Group type: EXPERIMENTAL
Intervention: Temporary abdominal aortic occlusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bilateral internal iliac artery occlusion
Number of subjects: 105
Study: 25159300

Group type: EXPERIMENTAL
Intervention: 20 mg of teneligliptin every day (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 20 mg of teneligliptin every other day (Group B)
Number of subjects: 51
Study: 23017585

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily containing 1·2 × 10(9) colony-forming units for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo - same product without bacteria for 12 weeks
Number of subjects: 60
Study: 21771722

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2505

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 2505
Study: 19500037

Group type: EXPERIMENTAL
Intervention: Higher levels of IgG to VSA-PAM
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Higher levels of opsonizing antibodies to CS2 IEs
Number of subjects: 141
Study: 16371604

Group type: EXPERIMENTAL
Intervention: iv iron alone (200 mg of iron sucrose on POD 1, 2, and 3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of iv iron and EPO (600 U x kg(‐1) on POD 1 and 3)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38
Study: 12527999

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 76
Study: 12534557

Group type: EXPERIMENTAL
Intervention: Air cleaners in the living room and bedroom for 12 months and using high efficiency particulate air filter vacuum cleaners
Number of subjects: 30

Group type: COMPARATOR
Intervention: Using high efficiency particulate air filter vacuum cleaners alone
Number of subjects: 30
Study: 9706322

Group type: EXPERIMENTAL
Intervention: Schematic maps
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 95

Group type: COMPARATOR
Intervention: Essay group (control)
Number of subjects: 95
Study: 7753750

Group type: EXPERIMENTAL
Intervention: Omeprazole (Prilosec)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 2225558

Group type: EXPERIMENTAL
Intervention: Calcium infusion at 15 ml/hour using 10% CaCl2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcium infusion at 20 ml/hour using 10% CaCl2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcium infusion at 10 ml/hour using 10% CaCl2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dialyzate with 1.5 mmol/l calcium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dialyzate with 1.75 mmol/l calcium
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dialyzate calcium-free with varying calcium infusion rates
Number of subjects: 6
Study: 487912

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g per day for 4 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Antacid (210 ml/day for 4 weeks)
Number of subjects: 51
Study: 31375051

Group type: EXPERIMENTAL
Intervention: Dasotraline 4 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 31256084

Group type: EXPERIMENTAL
Intervention: Cognitive-motor exergame training (CMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 24
Study: 27417142

Group type: EXPERIMENTAL
Intervention: Increased sleep duration (1.5 hours/night for 1 week)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Decreased sleep duration (1.5 hours/night for 1 week)
Number of subjects: 37
Study: 25762165

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day for 1 week, then 40 mg/day for 3 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vitamin B12 (VB12) 1.5 mg/day for 4 weeks
Number of subjects: 34
Study: 24145488

Group type: EXPERIMENTAL
Intervention: Venous pool technique (VPT) for blood sampling
Number of subjects: 74

Group type: COMPARATOR
Intervention: Needlestick technique
Number of subjects: 74
Study: 21469249

Group type: EXPERIMENTAL
Intervention: Micro-current reflexotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Medicamental therapy (Control)
Number of subjects: 84
Study: 19396541

Group type: EXPERIMENTAL
Intervention: Low-vision rehabilitation using MP-1 biofeedback examination (10 weeks, 10 training sessions of 10 min each, once a week)
Number of subjects: 5
Study: 16309929

Group type: EXPERIMENTAL
Intervention: Therapeutic education and functional readaptation (TEFR) added to conventional (pharmacological) treatment (n=51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional (pharmacological) treatment only (n=49)
Number of subjects: 100
Study: 15270367

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Handgrip Dynamometry (HGD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Orthostatic Tolerance Test (OTT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Recovery Phase after CPT and HGD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Valsalva Maneuver (VM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Controlled Breathing Test for sinus arrhythmia (SA)
Number of subjects: 28
Study: 11301848

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin as induction therapy followed by concomitant chemoradiation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combinations (with gemcitabine, paclitaxel, or vinorelbine) as induction therapy
Number of subjects: 187
Study: 9224195

Group type: EXPERIMENTAL
Intervention: Car seat distribution with education on car restraint use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Car seat distribution without education
Number of subjects: 0
Study: 8424584

Group type: EXPERIMENTAL
Intervention: Low-dose polyunsaturated fatty acids from fish oil (350 mg daily) in microencapsulated form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-dose polyunsaturated fatty acids from fish oil (350 mg daily) in gelatine capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations of fish oil
Number of subjects: 12
Study: 29701067

Group type: EXPERIMENTAL
Intervention: ≥65 years age group
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Younger age group
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Non-chest symptom clusters
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Atypical and typical symptom clusters in ≥65 years group
Number of subjects: 1211
Study: 27444039

Group type: EXPERIMENTAL
Intervention: Atomoxetine oral solution 50 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atomoxetine capsules 50 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atomoxetine oral solution
Number of subjects: 42
Study: 24840583

Group type: EXPERIMENTAL
Intervention: Taped condition during walking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Taped condition during jogging
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untaped condition
Number of subjects: 15
Study: 22104298

Group type: EXPERIMENTAL
Intervention: Calisthenics exercises for 6 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pilates exercises for 6 months
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no specific training)
Number of subjects: 107
Study: 21102973

Group type: EXPERIMENTAL
Intervention: Local anesthetic only (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local anesthetic mixed with non-particulate betamethasone (Group II)
Number of subjects: 40
Study: 18523316

Group type: EXPERIMENTAL
Intervention: Changes in lipid profile (average LDL decreased by 28%, average HDL increased by 8%)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Patients with CAD regression (n = 756)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Changes in lipid profile
Number of subjects: 1315
Study: 16150136

Group type: EXPERIMENTAL
Intervention: phe-free protein substitute supplemented with EFA (test-treatment group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: phe-free, fat-free protein substitute (control group)
Number of subjects: 43
Study: 12849766

Group type: EXPERIMENTAL
Intervention: Patients with HD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gene-carriers of HD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 10388983

Group type: EXPERIMENTAL
Intervention: Macroalbuminuric subjects (AER = 300 mg/day)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Entire group
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Normoalbuminuric DCCT group
Number of subjects: 1160
Study: 8637536

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 81
Study: 1642821

Group type: EXPERIMENTAL
Intervention: Single inclinometry
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Double inclinometry
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Back range-of-motion inclinometry
Number of subjects: 8

Group type: COMPARATOR
Intervention: B-200
Number of subjects: 8
Study: 6472539

Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31829921

Group type: EXPERIMENTAL
Intervention: 5% Date Palm Kernel Extract (DPKE) cream applied twice daily for 8 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 43
Study: 30596725

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs)
Number of subjects: 2381
Study: 26418444

Group type: COMPARATOR
Intervention: C2F6 gas endotamponade (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Densiron 68 tamponade (Group B)
Number of subjects: 21
Study: 25147029

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 500
Study: 22766770

Group type: EXPERIMENTAL
Intervention: Souvenaid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iso-caloric control product
Number of subjects: 0
Study: 19577859

Group type: EXPERIMENTAL
Intervention: 3 months short-term neoadjuvant androgen deprivation (STAD) before and during prostatic irradiation (XRT)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: 6 months short-term neoadjuvant androgen deprivation (STAD) before and during prostatic irradiation (XRT)
Number of subjects: 802

Group type: COMPARATOR
Intervention: XRT alone
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: TTBF measured from end of radiation (ERT)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: TTBF measured from testosterone recovery
Number of subjects: 802
Study: 18187428

Group type: EXPERIMENTAL
Intervention: PGA (60 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (without PGA)
Number of subjects: 24
Study: 15890731

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix 0.25 mg daily starting when the leading follicle reached 14 mm)
Number of subjects: 87

Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 87
Study: 12626212

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) using a combination of transdermal estradiol gel and a progestin other than MPA
Number of subjects: 3175
Study: 9509074

Group type: COMPARATOR
Intervention: Loose diet (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Strict diet (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 8208872

Group type: EXPERIMENTAL
Intervention: Galanthamine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Galanthamine 15 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2563217

Group type: EXPERIMENTAL
Intervention: Somatostatin pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral potassium pretreatment
Number of subjects: 10
Study: 1164890

Group type: EXPERIMENTAL
Intervention: Sisomicin (1.0 mg/kg body-weight, 2-3 times daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gentamicin (1.0 mg/kg body-weight, 1-hour infusion)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sisomicin (1.0 mg/kg body-weight, 1-hour infusion)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tobramycin (1.0 mg/kg body-weight, 1-hour infusion)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 36
Study: 30616534

Group type: EXPERIMENTAL
Intervention: Axitinib titration (5 mg bid)
Number of subjects: 112
Study: 28253404

Group type: EXPERIMENTAL
Intervention: Orthokeratology (ortho-k) lenses
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (single-vision spectacles)
Number of subjects: 136
Study: 25431484

Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SDAI
Number of subjects: 102
Study: 23651793

Group type: EXPERIMENTAL
Intervention: 1 × 30 mg/mL subcutaneous injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: 2 × 15 mg/mL subcutaneous injections
Number of subjects: 14
Study: 21060995

Group type: EXPERIMENTAL
Intervention: BZP/TFMPP (100/30 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19548931

Group type: EXPERIMENTAL
Intervention: Charge-Coupled Device (CCD) system
Number of subjects: 206

Group type: COMPARATOR
Intervention: Photostimulable Phosphor (PSP) system
Number of subjects: 206
Study: 17308499

Group type: EXPERIMENTAL
Intervention: 80 mg soy-derived isoflavones
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 15183623

Group type: EXPERIMENTAL
Intervention: Compression treatment with superficial venous surgery
Number of subjects: 500

Group type: COMPARATOR
Intervention: Compression treatment alone
Number of subjects: 500
Study: 11546660

Group type: EXPERIMENTAL
Intervention: Adrenergic blockade (prazosin hydrochloride and timolol malate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adrenergic blockade (prazosin hydrochloride and timolol malate) during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study: 9514434

Group type: EXPERIMENTAL
Intervention: Postanal repair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total pelvic floor repair
Number of subjects: 20
Study: 7527916

Group type: EXPERIMENTAL
Intervention: DRE + TRUS
Number of subjects: 2

Group type: COMPARATOR
Intervention: PSA
Number of subjects: 2
Study: 2500848

Group type: EXPERIMENTAL
Intervention: Exogenous, microbial beta-D-galactosidase (lactase)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 820708

Group type: EXPERIMENTAL
Intervention: 20 mg of synthetic TRH three times a day, 30 minutes before breast feeding
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31358616

Group type: EXPERIMENTAL
Intervention: Muscle biopsy reading by experts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Holistic muscle biopsy interpretation
Number of subjects: 24
Study: 29446785

Group type: EXPERIMENTAL
Intervention: Salso-bromo-iodine thermal water solution administered by nasal douche twice/day for 10 days a month for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isotonic saline administered by nasal douche twice/day for 10 days a month for 3 months
Number of subjects: 80
Study: 27291502

Group type: EXPERIMENTAL
Intervention: Papilla base incision (PBI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sulcular incision (IS)
Number of subjects: 24
Study: 25231186

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22369223

Group type: EXPERIMENTAL
Intervention: Viewing negative pictures
Number of subjects: 70

Group type: COMPARATOR
Intervention: Viewing positive pictures
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trait restriction
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trait temptation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 70
Study: 20815272

Group type: EXPERIMENTAL
Intervention: Gutuo Qingfu Decoction (GQD) via gastro-enteric perfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study: 17413915

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment blockade (FICB) with 1.0% mepivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo FICB with 0.9% saline and intramuscular injection of 0.1 mg/kg morphine
Number of subjects: 48
Study: 16237512

Group type: EXPERIMENTAL
Intervention: Group education session (2 hours) supplemented by brief individualized session (10 minutes)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 359
Study: 11849633

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Ortho Evra/Evra)
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Oral contraceptive
Number of subjects: 1785
Study: 10492057

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) administered during the ovulatory phase (days 13-16 post-onset of menses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) administered during the luteal phase (days 22-26 post-onset of menses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) administered during the follicular phase (days 2-6 post-onset of menses)
Number of subjects: 10
Study: 8724047

Group type: EXPERIMENTAL
Intervention: Health education intervention emphasizing HIV transmission and condom use
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 2160
Study: 2206774

Group type: EXPERIMENTAL
Intervention: OK-432 (5 KE orally for 7-14 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study: 7034755

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg orally
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (placebo not specified)
Number of subjects: 9
Study: 30616653

Group type: EXPERIMENTAL
Intervention: Individualized context-based SDM face-to-face training (IG I)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Web-based interactive SDM online training (IG II)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (CG) receiving no SDM training
Number of subjects: 162
Study: 28035542

Group type: EXPERIMENTAL
Intervention: CZSG (12 mg orally, thrice daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: KFX (10 mL orally, thrice daily)
Number of subjects: 120
Study: 25261418

Group type: COMPARATOR
Intervention: Standard dose (400/100 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Increased dose (600/150 mg)
Number of subjects: 154
Study: 25049340

Group type: EXPERIMENTAL
Intervention: Behavioral intervention targeting both child and parent, including diet and activity education over 12 months (13 sessions) followed by 12-month follow-up (3 sessions).
Number of subjects: 105

Group type: COMPARATOR
Intervention: Information control (IC) targeting weight control only in the child.
Number of subjects: 105